The standard treatment of LS is long-term application of recombinant IGF1, which increases growth velocity and improves adult height, but it may lead to a spectrum of side effects, in particular hypoglycemia ([9], [10]; reviewed in [11]). This evidence concerns the gene IGF1 and Leigh syndrome.